

Symposium 206



From the New and Complex Concepts to the Real Patient: Science and Clinic in IBD

March 31 – April 1, 2017

Meliá Castilla Hotel

Madrid, Spain



Program

Awarded
with

11

CME credits

▶	Preface	4
▶	Scientific Program	6
▶	Posters	10
▶	List of Speakers, Moderators and Scientific Organizers	20
▶	Information	24

11 credit hours (CME) have been awarded for the Symposium 206 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology.

Preface

The field of inflammatory bowel diseases is growing: we meet more patients; we discover more genes and interleukins; we develop new tests and drugs. Not long ago, general gastroenterologist took care of most IBD patients. Today, complex multidisciplinary units are doing the task in many centers around the world. IBD is becoming a vast and complex field.

We need new tools to deal with complexity, new tools helping us to discern what really matters. In understanding the key aspects of research we will improve our practice, the health of our patients and social welfare.

Symposia, organized by the Falk Foundation are one of these tools. They gather people who are passionate for IBD to share their knowledge: from basic science to socioeconomic analysis, from the newest interleukin to the oldest (but still useful) drug. This is the first magic concept: sharing. We meet to share ideas in a friendly environment. We share science, clinical experience and multinational proficiency. This collaboration will yield the second magic concept: learning. Most experts in these symposia are generous enough to share their knowledge with others. Nevertheless, and more importantly, they are eager for new ideas, open to learn from newcomers. We hope everybody will come back home after this meeting even more passionate about IBD and everything it involves: research, teaching, and, of course, the huge commitment that is caring for our patients.

On behalf of the scientific organizers

Dr. Fernando Gomollón, Zaragoza



From the New and Complex Concepts to the Real Patient: Science and Clinic in IBD

March 31 – April 1, 2017

**Meliá Castilla Hotel
Madrid, Spain**

Registration:

Thursday, March 30, 2017
16.00 – 21.00 h
at the congress office

Scientific Organization:

S. Danese, Milan (Italy)
A. Dignass, Frankfurt (Germany)
J.P. Gisbert, Madrid (Spain)
F. Gomollón, Zaragoza (Spain)

Congress Venue:

Meliá Castilla Hotel
Calle del Capitán Haya, 43
28020 Madrid
Spain

**The Symposium 206 is organized
by Falk Foundation e.V.**

Information:

Dr. Fernando Gomollón
Hospital Clínico Universitario
„Lozano Blesa“
Avenida San Juan Bosco 15
50009 Zaragoza
Spain
Telephone: +34 976 76 57 00
Telefax: +34 976 76 57 87
E-Mail: fgomollon@gmail.com

Official Language:

English.
Simultaneous translation into Spanish.

Call for Posters:

A poster session will take place.
For details see page 10.



Friday, March 31, 2017

9.00 Opening remarks

F. Gomollón,
Zaragoza

Session I From basic to clinic

Chair: I. Dotan, Tel Aviv; D.T. Rubin, Chicago

9.10 Genes: So complex

I. Cleynen,
Leuven

9.30 Epigenetics in IBD

S. Schreiber,
Kiel

9.50 Microbiome: Much more complex

F. Guarner,
Barcelona

10.10 Clinic phenotypes: The final result of complexity

C. Lees,
Edinburgh

10.30 **Coffee break with poster session**

Session II Diagnosis

Chair: A. López San Román, Madrid; G. Rogler, Zurich

11.00 The concepts are changing

G.J. Mantzaris,
Athens

11.20 Biomarkers

B.E. Sands,
New York

11.40 Imaging

G. Fiorino,
Milan

12.00 A step further: Individual prediction

D.T. Rubin,
Chicago

12.20 **Lunch break with poster session**



Friday, March 31, 2017

Session III The complex patient

Chair: G.J. Mantzaris, Athens; B.E. Sands, New York

- | | | |
|--------------|--|--|
| 13.40 | Ready to use cells? | M. Allez,
Paris |
| 14.00 | Tandem talk: Stenosis | M. Esteve,
Barcelona
A. Spinelli,
Milan |
| 14.30 | Chromoendoscopy | B. Sicilia,
Burgos |
| 14.50 | Treatment after cancer | L. Beaugerie,
Paris |
| 15.20 | Infections in inflammatory bowel disease | E. Domènech,
Badalona |
| 15.40 | Coffee break with poster session | |

Session IV Classic treatments: Do they really work?

Chair: Y. González Lama, Madrid; F. Magro, Porto

- | | | |
|--------------|---------------------------------------|------------------------------|
| 16.10 | Mesalazine | B. Siegmund,
Berlin |
| 16.30 | Thiopurines versus methotrexate | P.D.R. Higgins,
Ann Arbor |
| 16.50 | Calcineurin inhibitors, still a role? | E.F. Stange,
Tübingen |

Special Lecture

Chair: F. Gomollón, Zaragoza; B.E. Sands, New York

- | | | |
|--------------|---|-----------------------------|
| 17.10 | The preclinical phase of IBD: Road to prevention? | J.-F. Colombel,
New York |
| 17.40 | End of afternoon session | |



Saturday, April 1, 2017

Session V

Biologics, the end of the story?

Chair: J.-F. Colombel, New York; A. Dignass, Frankfurt

- | | | |
|--------------|---|----------------------------|
| 9.00 | Anti-TNFs: Lessons from 18 years | G. van Assche,
Leuven |
| 9.20 | Vedolizumab: What we do know | W.J. Sandborn,
La Jolla |
| 9.40 | Biosimilars: The clinical experience | F. Gomollón,
Zaragoza |
| 10.00 | New molecules | S. Danese,
Milan |
| 10.20 | New small molecules | G. Rogler,
Zurich |
| 10.40 | Coffee break with poster session | |

Session VI

From drugs to strategies: The long term plan

Chair: S. Danese, Milan; A. Sturm, Berlin

- | | | |
|--------------|--|------------------------------|
| 11.10 | Early treatment: Hitting hard? | L. Peyrin-Biroulet,
Nancy |
| 11.30 | How to deal with the patient – Focus on observational data | F. Magro,
Porto |
| 11.50 | Preventing of recurrence | P. Irving,
London |
| 12.10 | The “simple” ulcerative colitis patient | A. Sturm,
Berlin |
| 12.30 | Lunch break with poster session | |



Saturday, April 1, 2017

Special Lecture

Chair: A. Dignass, Frankfurt; F. Gomollón, Zaragoza

- | | | |
|--------------|--------------------------------------|----------------------------|
| 13.45 | The future of treatments | W.J. Sandborn,
La Jolla |
| 14.15 | Presentation of poster awards | J.P. Gisbert,
Madrid |
| | | A. Dignass,
Frankfurt |

Session VII The clinical scenarios

Chair: J.P. Gisbert, Madrid; F. Gomollón, Zaragoza

- | | | |
|--------------|---|-----------------------------|
| 14.30 | When to stop therapy in IBD | E. Louis,
Liège |
| 14.50 | Coffee break with poster session | |
| 15.15 | The simple Crohn's disease patient | J.O. Lindsay,
London |
| 15.35 | Surgery: "Marker of failure" | T. Oresland,
Lorenskog |
| 15.55 | Value based care in inflammatory bowel diseases | D.W. Hommes,
Los Angeles |
| 16.15 | Closing remarks | J.P. Gisbert,
Madrid |

Poster Session

Posters will be exhibited on March 31 and April 1, 2017 in the Meliá Castilla Hotel. The authors will be in attendance during coffee and lunch breaks on both days.

1. Inflammatory bowel disease in the UK: Is care improving?
L. Alrubaiy, I. Arnott, A. Protheroe, M. Roughton, J.G. Williams (Swansea, Edinburgh, London, GB)
2. Clinicians' knowledge about the ionizing radiation of the common investigations used in inflammatory bowel disease
L. Alrubaiy, S. Al-Rubaye, I. Rikaby, C.L. Ch'ng (Swansea, London, GB)
3. Influence of TGF-beta1 expression, -509C/T polymorphism and clinical correlations in gastric cancer patients
Y. Ananiev, I.M. Manolova, E. Alexandrova, M.V. Gulubova (Stara Zagora, BG)
4. Fecal microbiome in patients with prolonged use of nonsteroidal anti-inflammatory drugs
A.V. Antonenko, T.V. Beregova, A.S. Svintsitskiy (Kiev, UA)
5. The hematological anomalies in inflammatory bowel disease
D. Badea, M. Badea, A.-M. Genunche-Dumitrescu, P. Mitrut, S. Mitran, A. Badea (Craiova, RO)
6. Psychosocial impact of inflammatory bowel disease and its practice management as perceived by patients and physicians in Spain. The ENMENTE Project
M. Barreiro-de Acosta, M. Gobbo, M. Canas, A. Panadero, Y. Modino, J. Guardiola, L. Cea-Calvo, B. Julia, C. Romero, L. Carmona, I. Marin-Jimenez (Santiago de Compostela, Madrid, Barcelona, ES)
7. Intra-abdominal abscesses complicating Crohn's disease. Clinical and therapeutic features
N. Bel Hadj, I. Ben Aounallah, M. Cheikh, H. Romdhane, R. Ennaifer, H. Ben Nejma (Tunis, TN)
8. Extraintestinal manifestations in inflammatory bowel disease
E. Ben Jazia, S. Mrabet, I. Akkari, A. Atig (Sousse, TN)
9. Inflammatory bowel disease and Sweet's syndrome: An uncommon association
E. Ben Jazia, S. Mrabet, I. Akkari, A. Atig (Sousse, TN)
10. Venous thromboembolism with inflammatory bowel disease
M. Ben Khelifa, O. Daboussi, L. Mouelhi, F. Houissa, K. El Jery, Y. Said, M. Salem, R. Dabbech, T. Najjar (Tunis, TN)
11. Factors associated with positive tuberculosis screening in patients with inflammatory bowel disease and efficacy of the screening strategy
N. Ben Mustapha, A. Labidi, M. Fekih, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)
12. Impact of overweight on Crohn's disease
N. Ben Mustapha, O. Gharbi, A. Mensi, A. Labidi, M. Fekih, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)

13. Quality of care and opportunities for improvement in the management of hospitalized for severe ulcerative colitis
Y. Ber, M. Dominguez, Y. Arguedas, O. Rivas, L. Olivan, B. Sanchez, J. Rodriguez, M. Montoro (Huesca, ES)
14. Characterization of human intestinal macrophage subsets in health and inflammatory bowel disease
D. Bernardo, I. Mora-Gutierrez, A.C. Marin, A. Diaz-Guerra, R. Caminero-Fernandez, M. Caldas, F. De la Morena, M. Jimenez, M. Chaparro, J.P. Gisbert (Madrid, ES)
15. A viral FLIP homologue is able to disrupt intestinal immune homeostasis in vivo
B. Buchen, C. Günther, M. Stürzl, E. Cesarman, G. Ballon, M.F. Neurath, C. Becker (Erlangen, DE; New York, Lake Success, US)
16. Study of fatigue, anxiety, depression, quality of life and work impairment in IBD
P. Camo Monterde, H. Llop Serrano, R. Vicente Lidon, J.M. Boudet Barraca, P. Corsino Roche, J. Gotor Delso, S. Garcia-Lopez (Zaragoza, ES)
17. Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: Efficacy and safety in five years of follow-up
C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, G. Lecca, C. Corrado, P. Vernia, P. Paoluzi, E.S. Corazziari (Rome, IT)
18. Association between anti-TNF serum levels and mucosal healing (MH) in inflammatory bowel disease (IBD)
M. Chaparro, M. Barreiro-de Acosta, A. Echarri, R. Almendros, J. Barrio, J. Llaó, F. Gomollón, M. Vera, J.L. Cabriada, J. Guardiola, I. Guerra, B. Beltran, O. Roncero, D. Busquets, C. Taxonera Samsó, X. Calvet, R. Ferreira, V. Ollero Pena, M.G. Donday, A. Garre, A. Godino, A. Diaz, J.P. Gisbert (Madrid, Santiago de Compostela, Coruna, Valladolid, Barcelona, Zaragoza, Majadahonda, Vizcaya, Valencia, Ciudad Real, Girona, Sabadell, ES)
19. Malnutrition in Tunisian Crohn's disease patients
M. Cheikh, I. Ben Aounallah, H. Romdhane, R. Ennaifer, H. Ben Nejma, N. Bel Hadj (Tunis, TN)
20. Significant disabling anxiety as a side effect with anti-TNFs necessitating cessation of treatment. More common than we thought
V. Cambridge, J.D. Linehan, B. Colleypriest (Bath, GB)
21. Magnetic enterography and Crohn's disease activity index: The correlation between imaging technique and clinical index of disease activity
M. Crncevic Urek, M. Vukelic-Markovic, J. Curic, M. Simic, A. Crnogorac, T. Bradic, L. Prka, M. Banic (Zagreb, HR)
22. Onset-time of acute severe colitis in the course of an inflammatory bowel disease: Is it a prognostic factor?
W. Dahmani, N. Elleuch, M. Ksiai, A. Hammami, H. Jaziri, A. Ben Slama, A. Jmaa (Sousse, TN)

23. Telemedicine enables a safe shift from examination room based care to personalized care for inflammatory bowel disease: A pragmatic randomized multicenter trial with myIBDcoach
M.J. de Jong, A.E. van der Meulen-de Jong, M.J.L. Romberg-Camps, M.C.J.M. Becx, M. Cilissen, J.P. Maljaars, A.A. van Bodegraven, N. Mahmmod, T. Markus, W.M. Hameeteman, G. Dijkstra, A.A.M. Masclee, A. Boonen, D.M. Jonkers, A. van Tubergen, M.J. Pierik (Maastricht, Leiden, Sittard-Geleen, Nieuwegein, Woerden, Groningen, NL)
24. Aeromonas infection in inflammatory bowel disease patients
A. Diaz, H. Martinez, T. Vicente, P. Munoz, L. Menchén, E. Bouza, I. Marin-Jimenez (Madrid, ES)
25. Expression of pro-inflammatory and apoptotic genes is associated with therapy in Crohn's disease patients – A pilot study
S. Dragasevic, B. Stankovic, A. Sokic-Milutinovic, S. Lukic, T. Alempijevic, N. Kotur, G. Nikcevic, S. Pavlovic, T. Milosavljevic, M. Ivanovic, D. Popovic (Belgrade, RS)
26. Screening for liver diseases in IBD patients with non-invasive fibrosis scores
A. Egresi, A. Szilvas, K. Hagymasi, G. Lengyel, K. Szentmihalyi, A. Blazovics (Budapest, HU)
27. Liver biological abnormalities in inflammatory bowel diseases
N. Elleuch, S. Mrabet, A. Ben Slama, H. Jaziri, A. Hammami, A. Braham, S. Ajmi, M. Ksiao, A. Jmaa (Sousse, TN)
28. Re-phrasing the question: A simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease
T. Engel, B. Ungar, G. Ben-Haim, N. Levhar, R. Eliakim, S. Ben Horin (Ramat Gan, Tel-Aviv, Tel Hashomer, IL)
29. Results of medical treatment in symptomatic stenosing ileal disease during Crohn's disease and predictive factors of surgical treatment
M. Fekih, M. Amri, N. Ben Mustapha, M. Hafi, A. Labidi, M. Serghini, J. Boubaker, A. Filali, A. Mensi, N. Bellil (Tunis, TN)
30. Long term outcome of Crohn's disease patients treated with methotrexate: A retrospective monocenter study
M. Fekih, A. Labidi, I. Jemni, A. Siala, N. Ben Mustapha, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)
31. Frequency of the metabolic syndrome during inflammatory bowel disease
M. Fekih, A. Labidi, N. Bellil, A. Mensi, I. Jemni, N. Ben Mustapha, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)
32. Prevalence and risk factors of overweight and obesity in Crohn's disease patients
M. Fekih, A. Labidi, N. Bellil, A. Mensi, N. Ben Mustapha, J. Boubaker, M. Serghini, A. Filali (Tunis, TN)

33. Lipid profile in inflammatory bowel disease under maintenance with anti-TNF: A prospective longitudinal cohort study
R. Ferreiro-Iglesias, J. Lopez, A. Lorenzo-González, J.E. Dominguez-Muñoz, M. Barreiro-de Acosta (Santiago de Compostela, ES)
34. Clinical outcomes following open label switching from Remicade® to Remsima® and an assessment of outcomes in infliximab naïve inflammatory bowel disease patients treated with Remsima® in a prospective United Kingdom observational cohort study
H. Freer, V. Cambridge, B. Collepriest, J. Saunders (Bristol, Bath, GB)
35. Do patients with Crohn's disease in "deep" remission need the full body-weight based dose of azathioprine?
M. Galanopoulos, E. Archavlis, A. Christidou, P. Karatzas, K. Papamichail, L. Varytimiadis, N. Viazis, G.J. Mantzaris (Athens, Piraeus, Pikermi, GR)
36. Effect of infliximab on the Crohn's disease healing intestinal anastomosis in a rat model
M. Gazouli, C. Zeglinas, G. Karamanolis, A. Papalois, I. Papaconstantinou (Athens, Piraeus, Pikermi, GR)
37. A presumptive relationship between the therapeutic strategy for ulcerative colitis and the risk of developing a colorectal carcinoma
A.-M. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, C.I. Deliu, O.M. Diaconu, A. Badea (Craiova, RO)
38. Therapeutic changes and duration of usual treatments in ulcerative colitis in elderly patients
A.-M. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, C.I. Deliu, A. Badea (Craiova, RO)
39. Impact of overweight in Crohn's disease
O. Gharbi, N. Ben Mustapha, A. Labidi, M. Serghini, M. Fekih, J. Boubaker, A. Filali (Tunis, TN)
40. Abdominal tuberculosis of the gastrointestinal tract: Review of 25 cases
I. Ghribi, M. Ben Hmida, H. Elloumi, S. Ben Hmida, A. Belkhamza, S. Bouaziz, I. Cheikh (Bizerta, TN)
41. Efficacy and safety of endoscopic balloon dilatation in Crohn's disease
I. Ghribi, S. Bizid, M. Ghanem, B. Ben Slimane, K. Boughoula, H. Ben Abdallah, M.R. Bouali, M.N. Abdelli (Tunis, TN)
42. Comparison of clinical characteristics of Crohn's disease patients according to the age of diagnosis
I. Ghribi, M. Ben Hmida, H. Elloumi, S. Ben Hmida, A. Belkhamza, S. Bouaziz, I. Cheikh (Bizerta, TN)
43. Correlation between the imaging data and intraoperative findings during Crohn's disease
I. Ghribi, H. Hassine, N. Ben Mustapha, M. Fekih, J. Boubaker, A. Filali (Tunis, TN)

44. Iron deficiency anemia in Serbian IBD referral center
V. Gligorijevic, T. Knezevic-Ivanovski, S. Markovic, M. Protic (Belgrade, RS)
45. The introduction of biosimilar infliximab (CT-P13) through a managed switching programme generates significant cost savings with high levels of patient satisfaction
J.N. Gordon, S. Cotton, S. Garnish, L. McCabe, M. Brown, R. Saich, D. Lloyd, S. Rahmany (Winchester, GB)
46. Paneth cell dysfunction and death is directly linked to IFN signalling
C. Günther, B. Buchen, S. Wirtz, M.F. Neurath, C. Becker (Erlangen, DE)
47. The immunohistochemical assessment of metalloproteinases in IBD
K. Guzinska-Ustymowicz, A. Pryczynicz, A. Kemonia, M. Ustymowicz, A. Markowski, J. Zinczuk, K. Zareba (Bialystok, PL)
48. Expression of Fas/FasL in inflammatory bowel disease and colorectal cancer
K. Guzinska-Ustymowicz, M. Ustymowicz, A. Pryczynicz, A. Kemonia, A. Markowski, J. Zinczuk, K. Zareba (Bialystok, PL)
49. Impact of smoking on the clinical course and the therapeutic response of Crohn's disease
L. Hamzaoui, H. Ayadi, M. Medhioub, M. Bouassida, M.M. Azouz (Nabeul, TN)
50. Inflammatory bowel disease and thromboembolism
L. Hamzaoui, B. Bouchabou, M. Medhioub, M. Bouassida, M.M. Azouz (Nabeul, TN)
51. Does overweight modifies the clinical profile and the course of inflammatory bowel disease?
L. Hamzaoui, A. Ben Mohamed, M. Medhioub, B. Buchabou, M.M. Azouz (Nabeul, TN)
52. Calprotectin and C-reactive protein levels in patients can equally distinguish inflammatory and non-inflammatory diarrhea
D. Janelidze, N. Omanidze (Kiev, UA)
53. Introduction of an inflammatory bowel disease nurse led flexible sigmoidoscopy clinic improves patient care by initiating earlier treatment and saves clinic slots
H.E. Johnson, S.A. Weaver, S. McLaughlin (Bournemouth, GB)
54. Screening for enteric infection in inflammatory bowel disease patients contacting the IBD helpline and presenting with disease flares
H.E. Johnson, K. Wade, S.A. Weaver, S. McLaughlin (Bournemouth, GB)
55. MicroRNA expression in colon of active and inactive ulcerative colitis
S. Juzenas, J. Skieceviciene, V. Salteniene, J. Kupcinskas, G. Hemmrich-Stanisak, Z. Du, M. Hübenenthal, G. Kiudelis, L.V. Jonaitis, A. Franke, L. Lupinskas (Kaunas, LT; Kiel, DE)
56. Intestinal bacteria composition and translocation of bacteria at the inflammatory bowel disease
G. Karamanolis, S. Vrakas, K.C. Mountzouris, G. Michalopoulos, G. Papatheodoridis, C. Tzathas, M. Gazouli (Athens, Piraeus, GR)

57. Increased paracellular permeability induced by adherent invasive *E. coli* LF82 in human ileum is inhibited by blocking the CEACAM6 receptor
A.V. Keita, O. Yakymenko, B. Chassaing, J.D. Söderholm (Linköping, SE; Clermont-Ferrand, FR)
58. Fecal calprotectin as suitable biomarker in assessment of histological and endoscopic disease activity
T. Knezevic-Ivanovski, S. Knezevic-Ušaj, V. Gligorijević, S. Marković, P. Svorčan, M. Protić (Belgrade, Novi Sad, RS)
59. Irritable bowel syndrome correction during pregnancy
V.K. Kondratiuk, K.O. Kondratiuk, I.M. Nikitina (Kiev, Sumy, UA)
60. A possible impact of *Helicobacter pylori*-related metabolic syndrome in patients with inflammatory bowel disease
J. Kountouras, K. Anastasiadou, P. Katsinelos, N. Giorgakis, C. Gkatsis, S. Polyzos, I. Venizelos, P. Papadopoulos, E. Stefanidis (Thessaloniki, GR)
61. Efficacy and safety of azathioprine in inflammatory bowel disease patients: Results of a Tunisian survey
M. Labbane, S. Zarrouk, K. Torjmane, S. Ouerdiane, Y. Bouteraa (Bizerta, TN)
62. Impact of endoscopic remission in patients with ulcerative colitis
A. Labidi, M. Serghini, N. Ben Mustapha, M. Fekih, L. Zouiten, J. Boubaker, A. Filali (Tunis, TN)
63. Impact of dietary fibers intake on disease outcome in inflammatory bowel disease patients
A. Labidi, N. Ben Mustapha, M. Serghini, M. Fekih, I. Zouiten, J. Boubaker, A. Filali (Tunis, TN)
64. Peripheral organs' autoimmunity is highly connected to the intestinal ecosystem's events
A. Lerner, T. Matthias (Haifa, IL; Wendelsheim, DE)
65. Gluten immunological side effects are detrimental to human health: The joint aspects
A. Lerner, T. Matthias (Haifa, IL; Wendelsheim, DE)
66. Soluble syndecan-1: A novel biomarker of intestinal damage in children with celiac disease
A. Lerner, D. Yablecovitch, A. Oren, S. Ben Horin, E. Fudim, R. Eliakim, F.M. Konikoff, U. Kopylo, T. Matthias (Ramat Gan, Tel Aviv, Kfar Saba, IL; Wendelsheim, DE)
67. Anti-enterocyte autoantibodies in celiac disease
A. Lerner, K. Rafail, P. Jeremias, T. Matthias, H.S. Winter (Wendelsheim, DE; Boston, US)
68. Joint's autoimmunity is highly connected to the intestinal ecosystem's events
A. Lerner, T. Matthias (Haifa, IL; Wendelsheim, DE)

69. Comparison of the reliability of 17 celiac disease associated biomarkers to reflect intestinal damage
A. Lerner, P. Jeremias, S. Neidhöfer, T. Matthias (Haifa, IL; Wendelsheim, DE)
70. Reaction rates in patients transferred from biologic to bio-similar treatment for IBD
G. Lloyd-Ford, M. Gordon (Newport, GB)
71. The prevalence of *Helicobacter pylori*-positive gastritis in children with inflammatory bowel disease: Preliminary study
J.M. Lotowska, M.E. Sobaniec-Lotowska, U. Daniluk, D.M. Lebensztejn, J. Reszec, E. Jarocka-Cyrta, S.B. Lotowska, M. Koda, L. Kanczuga-Koda, J. Daniluk (Bialystok, Olsztyn, PL)
72. Risk factors for recurrence of postoperative Crohn's disease – Single-center experience
S. Markovic, P. Svorcan, V. Gligorijevic, T. Knezevic-Ivanovski, S. Sreckovic, M. Nedeljkovic-Protic (Belgrade, RS)
73. The mechanisms of microbiota disorders' influence on intestinal motor function in patients with diabetes mellitus type 2 with enteropathy
G.S. Maslova, Y.A. Mangryka, I.M. Skrypyk (Poltava, UA)
74. New markers for celiac disease: Anti-neo-epitope human and microbial transglutaminases
T. Matthias, P. Jeremias, S. Neidhöfer, A. Lerner (Wendelsheim, DE; Haifa, IL)
75. Antibodies against neo-epitope tTg complexed to gliadin out perform the uncomplexed anti-tTg to follow rheumatic arthritis patients
T. Matthias, P. Jeremias, S. Neidhöfer, A. Lerner (Wendelsheim, DE; Haifa, IL)
76. Autoantibodies against CD74 – A new diagnostic marker for spondyloarthritis (SpA)
T. Matthias, E. Schweighard, S. Reuter, M. Köhler, J. Georgi, N. Baerlecken, T. Witte (Wendelsheim, Damp, Hannover, DE)
77. Anti-neo-epitope tTg complexed to gliadin vs. tTg for celiac disease diagnosis
T. Matthias, P. Jeremias, S. Neidhöfer, A. Lerner (Wendelsheim, DE; Haifa, IL)
78. Pediatric celiac disease, cryptogenic hypertransaminasemia and *Helicobacter pylori* infection among children with dysmotility-like dyspepsia
R. Maxim, A.V. Trifan, A. Plesa, I. Ciortescu, C. Cojocariu, O.C. Stoica, E. Moraru, C. Stanciu (Iasi, RO)
79. Association between MDR1 gene polymorphisms and the risk of ulcerative colitis in Serbian patients with inflammatory bowel disease
D. Mijac, I. Vukovic, S. Duranovic, D. Bojic, D. Popovic, D. Culafic, B. Bojic, V. Pravica, M. Markovic (Belgrade, RS)
80. A single-center experience in inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis
M. Mijic, I. Kosuta, N. Sobocan, T. Filipec-Kanizaj (Zagreb, HR)
81. Inflammatory bowel disease and kidney – Is there a connection?
I. Mikolasevic, L. Orlic, I. Krznaric-Zrnica, D. Stimac, M. Zutelija, S. Milic (Rijeka, HR)

82. Hepatic toxicity to azathioprine: A report of 4 cases
S. Mrabet, I. Akkari, A. Atig, E. Ben Jazia (Sousse, TN)
83. Health-related quality of life in inflammatory bowel disease in a Tunisian population
S. Mrabet, M. Ksaa, N. Elleuch, H. Jaziri, A. Ben Slama, A. Braham, S. Ajmi, A. Jmaa (Sousse, TN)
84. Inflammatory bowel disease in children: A multicentric Tunisian study
A. Mzoughi, M. Tfifha, S. Mrabet, S. Chouchene, B. Mahjoub, K. Ben Hlel, N. Zouari, S. Abroug (Sousse, Monastir, Mahdia, Kairouan, TN)
85. Inflammatory bowel disease and chronic pancreatitis in children – Single center experience
G. Oracz, K. Wejnarska, E. Kolodziejczyk, J. Kierkus (Warsaw, PL)
86. Unusual course of tuberculosis in a patient treated with infliximab for indeterminate colitis: A case report
V. Orsic Fric, V. Borzan (Osijek, HR)
87. Association of mir-146 rs2910164, miR-119a rs11614913 and miR-221 rs113054794 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease
I. Papaconstantinou, C. Kapizioni, E. Legaki, E. Xourgia, G. Karamanolis, A. Papailia, C. Tzathas, M. Gazouli (Athens, Piraeus, GR)
88. Vedolizumab and predictive factors of clinical response in Crohn's and ulcerative colitis patients
I. Parisi, R. Vega, L. Whitney, S. Bloom, S. McCartney (London, GB)
89. Source of initial referral, rate of pre-investigation clinical diagnosis test requested in a cohort of newly diagnosed colorectal cancer patients: The Poole Experience
S.D. Parry, S. Surgenor, E.J. Williams (Poole, GB)
90. Post investigation colorectal cancer rates (PI-CCR) including post-colonoscopy colorectal cancer rates (PC-CRC): The Poole Experience
S.D. Parry, R. Shephard, E.J. Williams (Poole, GB)
91. The influence of 5-aminosalicylic acid on thiopurine metabolism in inflammatory bowel disease
K. Pavlovska, M. Slaninka Miceska, P. Mishevskaa, L. Efremovska, J. Tonic Ribarska (Skopje, MK)
92. Usefulness of a multidisciplinary approach combining both rheumatology and gastroenterology for the assessment and treatment of inflammatory bowel disease patients
E. Perez-Pampin, R. Ferreira, A. Mera, J.E. Dominguez-Munoz, M. Barreiro-de Acosta (Santiago de Compostela, ES)
93. Ulcerative colitis – Factors and ways of evolution
O. Petrascu (Sibiu, RO)

94. Correlations between fecal calprotectin concentrations and clinical and endoscopic features in pediatric patients with inflammatory bowel disease
S. Pieczarkowski, K. Kowalska-Duplaga, P. Kwinta, P. Tomasiak, A. Wedrychowicz, K. Fyderek (Cracow, PL)
95. Predictive factors for osteoporosis in patients with inflammatory bowel disease – A study in a tertiary care center in Romania
R.C. Popa, A. Savin, I. Ugureanu, O. Gavrilescu, I. Popa, A.-M. Chiosa, M. Dranga, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)
96. Claudin-4 protein expression in ulcerative colitis
A. Pryczynicz, J. Zinzuk, K. Zareba, A. Markowski, A. Kemonia, K. Guzinska-Ustymowicz (Bialystok, PL)
97. In patients with IBD switching from originator infliximab (Remicade®) to biosimilar infliximab (CT-P13) is safe and effective
S. Rahmany, S. Cotton, S. Garnish, M. Brown, R. Saich, D. Lloyd, J.N. Gordon (Winchester, GB)
98. Comparison between procalcitonin and C-reactive protein as indicators of inflammatory bowel disease activity
Y. Rashid, A. Goil (Sohag, Qena, EG)
99. Systematic review of the clinical disease severity indices for inflammatory bowel disease
I. Rikaby, L. Alrubaiy, M. Sageer, H.A. Hutchings, J.G. Williams (Cardiff, Swansea, GB; Burlington, US)
100. Can the inflammatory bowel disease biologics registry lead to improved quality of care?
I. Rikaby, L. Alrubaiy, H.A. Hutchings, J.G. Williams (Cardiff, Swansea, GB)
101. Correlation of faecal calprotectin levels and pathohistological findings in patients with irritable bowel syndrome (IBS)
B. Rosic Despalatovic, A. Bratanic, D. Mayer, K. Vilovic (Split, HR)
102. Tacrolimus therapy in moderate-to-subacute ulcerative proctocolitis: A large single-centre case series
A. Saifuddin, A.W. Harris (Maidstone, Turnbridge Wells, GB)
103. The prevalence of vitamin B12 deficiency in patients with Crohn's disease
A. Savin, R.C. Popa, A.-M. Chiosa, C. Mihai, C. Cijevschi Prelipcean (Iasi, RO)
104. Factors associated with voluntary childlessness in women with IBD
C.P. Selinger, J. Ghorayeb, A. Madill (Leeds, GB)
105. The peculiarities of ulcerative colitis systemic manifestations
I.M. Skrypnyk, G.S. Maslova, R. Skrypnyk (Poltava, UA)
106. Pathogenetic mechanisms of liver injury in patients with non-specific inflammatory bowel disease
I.M. Skrypnyk, G.S. Maslova (Poltava, UA)

107. A very rare case of IgG4-related sclerosing cholangitis with associated IgG4-related pancreatitis in a pediatric patient with ulcerative pancolitis: A pathomorphological study
M.E. Sobaniec-Lotowska, J.M. Lotowska, U. Daniluk, D.M. Lebensztejn, D. Jaroslaw, E. Jarocka-Cyrta, J. Reszec (Bialystok, Olsztyn, PL)
108. The level of procalcitonin in patients with inflammatory bowel disease
O. Sorochan, O. Tatarчук, M. Stoykevich, N. Vinnik (Dnipripetrovsk, UA)
109. Activation of the bile acid receptor, farnesoid X receptor, may reduce ileal inflammatory cytokine expression in an animal model of diet-induced obesity
R.A. Speight, A. Whitehead, G. Patman, J.C. Mansfield, H. Reeves, J.A. Kirby (Newcastle upon Tyne, GB)
110. The impact of an open access, non-face to face nurse led inflammatory bowel disease service on service transformation and patient outcomes
K. Street, C. Bull, R.C. Reynolds, K. Railton, M. Ragheb, P. Kerr, A. Taylor Gonzales, A.R. Ansari (Redhill, Surrey, GB)
111. Modifying properties of symbiotic microorganisms (*Lactobacillus plantarum*) for immune response modulation in the complex therapy of IBD
G. Tereshchuk, D. Vatlitsov (Kiev, UA)
112. Azathioprine-induced severe gastritis in patients with inflammatory bowel disease
L. Varytimiadis, E. Archavlis, A. Christidou, P. Karatzas, M. Galanopoulos, E. Vienna, N. Viazis, G.J. Mantzaris (Athens, GR)
113. The complex action of hyperactivated *Lactobacillus plantarum* in the therapy of IBD
D. Vatlitsov, G. Tereshchuk (Kiev, UA)
114. Regulatory role of the transcription factor GATA-3 in ulcerative colitis and inhibition of experimental colitis by GATA-3 specific DNAzyme technique
B. Weigmann, V. Popp, K. Gerlach, A. Turowska, H. Garn, R. Atreya, I.-C. Ho, H. Renz, M.F. Neurath (Erlangen, Marburg, DE; Boston, US)
115. The introduction of infliximab therapeutic drug level monitoring is associated with cost savings in a cohort of patients in a large District General Hospital
S. Whiteoak, H.E. Johnson, C. Hovell, S.A. Weaver, S. McLaughlin (Bournemouth, GB)
116. Post-oesophago-gastro-duodenoscopy (OGD) upper gastrointestinal (UGI) cancer rates: The Poole Experience
E.J. Williams, R. Shephard, S.D. Parry (Poole, GB)
117. Systematic review and meta-analysis: Is bowel preparation necessary in small bowel capsule endoscopy?
D.E. Yung, E. Rondonotti, C. Sykes, M. Pennazio, J.N. Plevris, A. Koulaouzidis (Edinburgh, GB; Como, IT)
118. The expression of CEACAM1 protein in inflammatory bowel diseases
J. Zinzuk, K. Zareba, K. Guzinska-Ustymowicz, A. Markowski, A. Kemonia, A. Pryczynicz (Bialystok, PL)

List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Matthieu Allez

Service de Gastroentérologie
Hôpital Saint-Louis
1 Ave. C. Vellefaux
75010 Paris
France
matthieu.allez@aphp.fr

Prof. Dr. Laurent Beaugerie

Department of Gastroenterology
Hôpital Saint-Antoine
184, Rue du Faubourg St.-Antoine
75571 Paris
France
laurent.beaugerie@sat.aphp.fr

Prof. Dr. Isabelle Cleynen

Department of Human Genetics
KU Leuven
Herestraat 49, bus 602
3000 Leuven
Belgium
isabelle.cleynen@med.kuleuven.be

Jean-Frederic Colombel, M.D.

Professor of Medicine
Gastroenterology & Hepatology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, NY 10029
USA
jean-frederic.colombel@mssm.edu

Dr. Silvio Danese

IRCCS in Gastroenterology
Istituto Clinico Humanitas IRCCS
Via Manzoni, 56
20089 Rozzano
Italy
sdanese@hotmail.com

Prof. Dr. Axel Dignass

Medizinische Klinik I
AGAPLESION
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info

Dr. Eugeni Domènech

Department of Gastroenterology
IBD Unit
Hospital Universitari Germans
Trias i Pujol
Carretera del Canyet s/n
08916 Badalona
Spain
eugenidomenech@gmail.com

Dr. Iris Dotan

Department of Gastroenterology
Tel Aviv Medical Center
Ichilov Hospital
6, Weizman Street
64239 Tel Aviv
Israel
irisd@tasmc.health.gov.il

Dr. Maria Esteve

Hospital Universitari
Mútua Terrassa
Plaza Dr. Robert 5
08221 Terrassa/Barcelona
Spain
mestevecomas@telefonica.net

Dr. Gionata Fiorino

IRCCS in Gastroenterology
Istituto Clinico Humanitas IRCCS
Via Manzoni, 56
20089 Rozzano
Italy
gionataf@gmail.com

Prof. Dr. Javier P. Gisbert

Hospital de la Princesa
Diego de Leon, 62
28006 Madrid
Spain
javier.gisbert@gmail.com

Dr. Fernando Gomollón

Hospital Clinico Universitario
Losano Blesa
Avenida San Juan Bosco 15
50009 Zaragoza
Spain
fgomollon@gmail.com

Dr. Yago González Lama

Gastroenterology and
Hepatology Department
Puerta de Hierro University Hospital
Manuel de Falla, 1.
28222 Majadahonda, Madrid
Spain
ygonzalezlama@telefonica.net

Dr. Francisco Guarner

Servicio de Patología Digestiva
Hospital General Vall d'Hebron
Paseo Vall d'Hebron 119
08035 Barcelona
Spain
fguarner@telefonica.net

Peter D.R. Higgins, M.D.

Associate Professor of Medicine
Division of Gastroenterology
Department of Internal Medicine
University of Michigan
SPC 5682, 1150 West Medical Center Drive
Ann Arbor MI 48109
USA
phiggins@med.umich.edu

Daan W. Hommes, M.D.

Professor of Medicine
UCLA Med-VA Greater
LA Healthcare Sys
Afd. MDL C4 P
11301 Wilshire Blvd.
Los Angeles CA 90073
USA
ibdcenter@mednet.ucla.edu

Dr. Peter Irving

Department of Gastroenterology
First Floor College House
North Wing, St Thomas' Hospital
Westminster Bridge Road
London SE1 7EH
Great Britain
peter.irving@gstt.nhs.uk

Dr. Charlie Lees

Gastrointestinal Unit
University of Edinburgh
Western General Hospital
Crewe Road
Edinburgh EH4 2XU
Great Britain
charlie.lees@ed.ac.uk

Dr. James O. Lindsay

Endoscopy Unit
The Royal London Hospital
Whitechapel
London E1 1BB
Great Britain
james.lindsay@bartshealth.nhs.uk

Dr. Antonio López San Román

Servicio de Gastroenterología y Hepatología
Hospital Universitario Ramon y Cajal
Cra Colmenar 9.1
28034 Madrid
Spain
alopez@meditex.es

Prof. Dr. Edouard Louis

Gastro-entérologie
C.H.U. Sart Tilman
Domain du Sart Tilman
4000 Liège
Belgium
edouard.louis@ulg.ac.be

Dr. Fernando Magro

Servico de Gastroenterologia
Hospital de S. Joao
Av. Prof. Hernani Monteiro
4200-319 Porto
Portugal
fm@med.up.pt

Prof. Dr. Gerassimos J. Mantzaris

Department of Gastroenterology
Evangelismos Hospital
45-47, Ypsilantou str., Kolonaki
106 76 Athens
Greece
gjmantzaris@gmail.com

Prof. Dr. Tom Oresland

Akershus
Universitetssykehus
Sykehusveien 25
1478 Lorenskog
Norway
tom.oresland@medisin.uio.no

Prof. Dr. Laurent Peyrin-Biroulet

Dept. of Hepato-Gastroenterology
Hôpitaux de Brabois
C.H.U. de Nancy
Allée du Morvan
54511 Vandoeuvre-Nancy
France
peyrinbiroulet@gmail.com

Prof. Dr. Dr. Gerhard Rogler

Klinik für Gastroenterologie
& Hepatologie
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
Switzerland
gerhard.rogler@usz.ch

David T. Rubin, M.D.

Professor of Medicine
Section of Gastroenterology,
Hepatology & Nutrition
The University of Chicago Medicine
5841 S. Maryland Ave.
MC4076, Room M410
Chicago, IL 60637
USA
drubin@medicine.bsd.uchicago.edu

William J. Sandborn, M.D.

Professor of Medicine
Division of Gastroenterology
University of California San Diego
9500 Gilman Drive, MC 0956
La Jolla, CA 92093
USA
wsandborn@ucsd.edu

Bruce E. Sands, M.D.

Professor of Medicine
Department of Gastroenterology
Mount Sinai School of Medicine
One Gustave L. Levy Place
New York, NY 10029
USA
bruce.sands@mssm.edu

Prof. Dr. Stefan Schreiber

Innere Medizin I
Universitätsklinikum
Schleswig-Holstein, Campus Kiel
Arnold-Heller-Straße 3 (Haus 6)
24105 Kiel
Germany
s.schreiber@mucosa.de

Dr. Beatriz Sicilia

IBD Unit
Servicio de Aparato Digestivo
Hospital Universitario de Burgos
Avenida Islas Baleares, 3
09006 Burgos
Spain
bsicilia4@gmail.com

Prof. Dr. Britta Siegmund

Gastroenterologie
Charité Universitätsmedizin
Campus Benjamin Franklin (CBF)
Hindenburgdamm 30
12203 Berlin
Germany
britta.siegmund@charite.de

Prof. Dr. Antonino Spinelli
Colon and Rectal Surgery Unit
Humanitas Research Hospital
Humanitas University
Via Manzoni, 56
20089 Rozzano
Italy
antonino.spinelli@humanitas.it

Prof. Dr. Eduard F. Stange
Abteilung Innere Medizin I
Medizinische Universitätsklinik
Otfried-Müller-Str. 10
72076 Tübingen
Germany
eduard.stange@rbk.de

Prof. Dr. Andreas Sturm
Innere Medizin/Gastroenterologie
DRK-Kliniken Westend
Spandauer Damm 130
14050 Berlin
Germany
a.sturm@drk-kliniken-berlin.de

Prof. Dr. Gert van Assche
Gastroentérologie
University Hospital Leuven
Herestraat 49
3000 Leuven
Belgium
gert.vanassche@uz.kuleuven.ac.be

Congress Office

During the Symposium 206

Meliá Castilla Hotel
Calle del Capitán Haya, 43
28020 Madrid
Spain

Telephone: +49 (0)175/7795327

Opening Hours:


Thursday, March 30, 2017	16.00 – 21.00 h
Friday, March 31, 2017	7.30 – 17.45 h
Saturday, April 1, 2017	8.30 – 16.30 h

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Airport

Madrid-Barajas Airport: <http://www.aeropuertomadrid-barajas.com/eng/>
(approx. 15 km from the congress venue)



Organized by:

FALK FOUNDATION e.V.



Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department

Telephone: +49 (0) 761/15 14-125

Telefax: +49 (0) 761/15 14-359

E-Mail: symposia@falk-foundation-symposia.org

www.falk-foundation-symposia.org